{"id":545887,"date":"2021-06-02T19:04:01","date_gmt":"2021-06-02T19:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545887"},"modified":"2021-06-02T19:04:01","modified_gmt":"2021-06-02T19:04:01","slug":"chronic-kidney-disease-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-gni-group-ltd-ibio-inc-icmedtech-inc-ipsen-sa-isarna-therapeutics-kbp-biosciences-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-kidney-disease-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-gni-group-ltd-ibio-inc-icmedtech-inc-ipsen-sa-isarna-therapeutics-kbp-biosciences-and-others_545887.html","title":{"rendered":"Chronic Kidney Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | GNI Group Ltd, iBio Inc, IC-MedTech Inc, Ipsen SA, Isarna Therapeutics, KBP BioSciences and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1622610139.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Kidney Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | GNI Group Ltd, iBio Inc, IC-MedTech Inc, Ipsen SA, Isarna Therapeutics, KBP BioSciences and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1622610139.jpeg\" alt=\"Chronic Kidney Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | GNI Group Ltd, iBio Inc, IC-MedTech Inc, Ipsen SA, Isarna Therapeutics, KBP BioSciences and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Chronic Kidney Disease Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Chronic Kidney Disease<\/strong> is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke. Some other health consequences of Chronic Kidney Disease include:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Anemia or low number of red blood cells<\/li>\n<li>Increased occurrence of infections<\/li>\n<li>Low calcium levels, high potassium levels, and high phosphorus levels in the blood<\/li>\n<li>Loss of appetite or eating less<\/li>\n<li>Depression or lower quality of life<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,<strong>&nbsp;&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-ckd-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Chronic Kidney Disease Pipeline<\/a> Insights, 2021,&rdquo;&nbsp;<\/strong>report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-kidney-disease-ckd-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-kidney-disease-ckd-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Chronic Kidney Disease Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AdAlta Ltd<\/li>\n<li>Allena Pharmaceuticals Inc<\/li>\n<li>apceth Biopharma GmbH<\/li>\n<li>Arch Biopartners Inc<\/li>\n<li>Astellas Pharma Inc<\/li>\n<li>AstraZeneca Plc<\/li>\n<li>Bayer AG<\/li>\n<li>BiOrion Technologies BV<\/li>\n<li>Boehringer Ingelheim GmbH<\/li>\n<li>Boryung Pharmaceutical Co Ltd<\/li>\n<li>Celgene Corp<\/li>\n<li>Certa Therapeutics Pty Ltd<\/li>\n<li>Conatus Pharmaceuticals Inc<\/li>\n<li>Corvidia Therapeutics Inc<\/li>\n<li>DiaMedica Therapeutics Inc<\/li>\n<li>Dimerix Bioscience Pty Ltd<\/li>\n<li>DiscoveryBiomed Inc<\/li>\n<li>DURECT Corp<\/li>\n<li>Epigen Biosciences Inc<\/li>\n<li>Galectin Therapeutics Inc<\/li>\n<li>GenKyoTex SA<\/li>\n<li>GNI Group Ltd<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-kidney-disease-ckd-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-kidney-disease-ckd-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Chronic Kidney Disease report covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Mid-stage products (Phase II and Phase I\/II)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-ckd-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Chronic Kidney Disease Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>AZD5718<\/li>\n<li>MEDI8367<\/li>\n<li>efepoetin alfa<\/li>\n<li>Verinurad<\/li>\n<li>Empagliflozin<\/li>\n<li>DDO-3055<\/li>\n<li>KBP-5074<\/li>\n<li>Doxercalciferol<\/li>\n<li>TRC101<\/li>\n<li>Pegol-Sihematide<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-kidney-disease-ckd-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-kidney-disease-ckd-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Chronic Kidney Disease Treatment Scenario and<\/strong> <strong>Chronic Kidney Disease Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Chronic Kidney Disease drugs?<\/li>\n<li>How many Chronic Kidney Disease drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Chronic Kidney Disease and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">&bull; Chronic Kidney Disease companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Pegol-Sihematide: Jiangsu Hansoh Pharmaceutical Co., Ltd.<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">AZD5718: AstraZeneca<\/p>\n<p style=\"text-align: justify;\">KBP-5074: KBP Biosciences<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease Key Companies<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease Key Products<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease Analyst Views<\/p>\n<p style=\"text-align: justify;\">Chronic Kidney Disease Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/chronic-kidney-disease-ckd-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-kidney-disease-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-gni-group-ltd-ibio-inc-icmedtech-inc-ipsen-sa-isarna-therapeutics-kbp-biosciences-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-ckd-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-ckd-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-ckd-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-kidney-disease-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-gni-group-ltd-ibio-inc-icmedtech-inc-ipsen-sa-isarna-therapeutics-kbp-biosciences-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Kidney Disease Pipeline Chronic Kidney Disease is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-kidney-disease-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-gni-group-ltd-ibio-inc-icmedtech-inc-ipsen-sa-isarna-therapeutics-kbp-biosciences-and-others_545887.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-545887","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545887"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545887\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}